Browsing by Author "Acevedo, M."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Achievement of treatment targets of cardiovascular risk factors in a pilot secondary prevention program in Chile
    (2008) Acevedo, M.; Kraemer, V.; Chamorro, G.; Krogh, G.; Munoz, A.; Corbalan, R.
  • No Thumbnail Available
    Item
    An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile
    (2022) Soto, J.A.; Melo-González, F.; Gutierrez-Vera, C.; Schultz, B.M.; Berríos-Rojas, R.V.; Rivera-Pérez, D.; Piña-Iturbe, A.; Hoppe-Elsholz, G.; Duarte, L.F.; Vázquez, Y.; Moreno-Tapia, D.; Ríos, M.; Palacios, P.A.; Garcia-Betancourt, R.; Santibañez, Á.; Mendez, C.; Diethelm-Varela, B.; Astudillo, P.; Calvo, M.; Cárdenas, A.; González, M.; Goldsack, M.; Gutiérrez, V.; Potin, M.; Schilling, A.; Tapia, L.I.; Twele, L.; Villena, R.; Grifoni, A.; Sette, A.; Weiskopf, D.; Fasce, R.A.; Fernández, J.; Mora, J.; Ramírez, E.; Gaete-Argel, A.; Acevedo, M.; Valiente-Echeverría, F.; Soto-Rifo, R.; Retamal-Díaz, A.; Muñoz-Jofré, N.; Meng, X.; Xin, Q.; Alarcón-Bustamante, E.; González-Aramundiz, J.V.; Le Corre, N.; Álvarez, M.J.; González, P.A.; Abarca, K.; Perret, C.; Carreño, L.J.; Kalergis, A.M.; Bueno, S.M.
  • Thumbnail Image
    Item
    Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults
    (2022) Melo González, Felipe; Méndez, Constanza; Peñaloza, H.F.; Schultz, B.M.; Piña Iturbe, A.; Ríos, M.; Moreno Tapia, D.; Pereira Sánchez, P.; Leighton, D.; Orellana, C.; Covarrubias, C.; Gálvez, N.M.S.; Soto, J.A.; Duarte, L.F.; Rivera Pérez, D.; Vázquez, Y.; Cabrera, A.; Bustos, S.; Iturriaga, C.; Urzua, M.; Navarrete, M.S.; Rojas, Á.; Fasce, R.; Fernández, J.; Mora, J.; Ramírez, E.; Gaete Argel, A.; Acevedo, M.; Valiente Echeverría, F.; Soto Rifo, R.; Weiskopf, D.; Grifoni, A.; Sette, A.; Zeng, G.; Meng, W.; González Aramundiz, J.V.; González, P.A.; Abarca, K.; Bueno, S.M.; Kalergis, A.M.
    The SARS-CoV-2 Omicron variant has challenged the control of the COVID-19 pandemic even in highly vaccinated countries. While a second booster of mRNA vaccines improved the immunity against SARS-CoV-2, the humoral and cellular responses induced by a second booster of an inactivated SARS-CoV-2 vaccine have not been studied. In the context of a phase 3 clinical study, we report that a second booster of CoronaVac® increased the neutralizing response against the ancestral virus yet showed poor neutralization against the Omicron variant. Additionally, isolated PBMCs displayed equivalent activation of specific CD4+ T cells and IFN-γ production when stimulated with a mega-pool of peptides derived from the spike protein of the ancestral virus or the Omicron variant. In conclusion, a second booster dose of CoronaVac® does not improve the neutralizing response against the Omicron variant compared with the first booster dose, yet it helps maintaining a robust spike-specific CD4+ T cell response.